NPPA Revises Prices of 543 Anti-Cancer Medicine Brands Under DPCO 2013: 30% Trade-Margin Cap Effective 9 November 2026

Why in News

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, has revised the Maximum Retail Prices (MRPs) of 543 anti-cancer medicine brands — comprising 1,085 formulations — with effect from 9 November 2026. The revision follows the NPPA's decision on 17 October 2026 to invoke Paragraph 19 of the Drug Price Control Order (DPCO), 2013 in public interest, capping trade margins on 137 non-scheduled anti-cancer drugs at 30%. All retailers, hospitals, and distributors are required to charge revised prices and display them prominently from today.

Background

Cancer is a major public-health challenge in India. According to the Indian Council of Medical Research (ICMR), India records approximately 14 lakh new cancer cases annually. The economic burden of cancer treatment is a leading cause of catastrophic health expenditure, pushing families into poverty. High retail prices of anti-cancer drugs — driven partly by excessive trade margins at the distributor and retailer level — have historically made these medicines unaffordable for a large section of patients.

India's pharmaceutical pricing architecture differentiates between scheduled drugs (whose ceiling prices are fixed by the NPPA under the DPCO 2013) and non-scheduled drugs (whose prices are market-determined, with manufacturers permitted an annual price increase of up to 10%). Anti-cancer drugs in this revision are non-scheduled; the NPPA cannot fix their ceiling prices directly but can rationalise trade margins under Paragraph 19.

Current Developments

• 17 October 2026: NPPA invoked Paragraph 19 of DPCO 2013 to rationalise trade margins on 137 non-scheduled anti-cancer drugs in public interest.
• 3 November 2026: NPPA updated the MRP list for 1,085 anti-cancer formulations across 543 brands.
• 9 November 2026: Revised MRPs take effect. All retailers and hospitals must charge reduced prices and display the revised MRP list.
• The revised list of brands is available on the NPPA portal and will be updated continuously as additional manufacturers submit revised pricing data.

Key Facts

• Authority invoking revision: NPPA (National Pharmaceutical Pricing Authority)
• Legal provision invoked: Paragraph 19, DPCO 2013 — allows the government to fix or regulate prices of non-scheduled drugs in public interest
• Number of drugs targeted: 137 non-scheduled anti-cancer drugs
• Brands revised: 543 (covering 1,085 formulations)
• Trade margin cap: 30%
• Effective date: 9 November 2026
• Earlier precedent: 2019 — government capped trade margins on 42 anti-cancer drugs at 30% (Hindustan Times, 28 February 2019)
• Nodal ministry: Ministry of Chemicals and Fertilizers → Department of Pharmaceuticals → NPPA

What is Trade Margin Rationalisation (TMR)?

Trade Margin Rationalisation (TMR) is a mechanism to control the difference between the manufacturing/import price of a drug and its MRP by capping the percentage margin that wholesalers and retailers are permitted to add. Unlike ceiling price fixation (which caps the absolute price), TMR targets the distribution chain mark-up. For the 137 anti-cancer drugs in this revision, the total trade margin (distributor + retailer) is capped at 30% on the price charged to the first-point buyer (typically a stockist or wholesaler).

Constitutional Provisions

• Article 47 (DPSP): The State shall regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties. Drug price control derives its constitutional legitimacy from this Directive.
• Entry 19, Union List: Import and export across customs frontiers of drugs — Union subject. Entry 19 and 20 of the Concurrent List cover drugs and poisons — both Parliament and State legislatures can legislate.
• Entry 20, Concurrent List: Economic and social planning — central coordination of pharmaceutical pricing policy.

Legal Framework

• Essential Commodities Act, 1955: Parent Act under which drug price control orders are issued. The DPCO 2013 is a subordinate legislation issued under Section 3 of this Act.
• Drug Price Control Order (DPCO), 2013: Key subordinate legislation regulating pharmaceutical prices. Paragraph 19 empowers the government to fix prices of non-scheduled formulations in public interest when the same are "essential" or "necessary." Companies must comply with revised MRPs within 30 days.
• Drugs and Cosmetics Act, 1940: Governs manufacture, sale, and distribution of drugs; licensing of manufacturers.
• National Pharmaceutical Pricing Authority (NPPA), 1997: Created by a Government of India Resolution — not a statutory body but an executive authority. It monitors pharmaceutical prices and implements price control under DPCO 2013.

Institutional Framework

• NPPA (National Pharmaceutical Pricing Authority): Autonomous body under Department of Pharmaceuticals; regulates and controls drug prices; monitors availability of medicines; enforces DPCO compliance.
• Department of Pharmaceuticals (DoP): Nodal department under Ministry of Chemicals and Fertilizers; policy on pharmaceutical sector including price control.
• Central Drugs Standard Control Organisation (CDSCO): Regulates drug quality and approval; works in tandem with NPPA on market access and quality.
• National Health Authority (NHA): Relevant because Ayushman Bharat – PM Jan Arogya Yojana (AB-PMJAY) beneficiaries benefit from price-capped anti-cancer drugs in empanelled hospitals.

Economic Dimensions

Cancer treatment can cost between ₹5 lakh and ₹30 lakh for a full course, depending on the type of cancer and the drugs involved. Targeted therapies (such as monoclonal antibodies and tyrosine kinase inhibitors) carry especially high MRPs. By capping trade margins at 30%, the NPPA aims to reduce out-of-pocket expenditure (OOP), which constitutes more than 60% of health expenditure in India — the second-highest in the world. Reduced drug prices also reduce the financial burden on government insurance schemes (AB-PMJAY) and state Arogya Mitras, stretching the coverage of public health spending.

Banking & financial angle: From a banking and insurance perspective, lower catastrophic health expenditure reduces Non-Performing Assets (NPAs) arising from health-related personal loan defaults, and reduces payouts under health insurance policies — particularly relevant for IBPS/RBI candidates studying health-linked financial stress indicators.

Social Dimensions

• Cancer disproportionately affects lower-income households due to late-stage diagnosis and inability to afford treatment.
• Women face a double burden: cervical and breast cancer are among the top cancer types in India, and women in rural areas have significantly lower access to screening and treatment.
• Price rationalisation supports India's Universal Health Coverage (UHC) goals under the National Health Policy 2017 and Sustainable Development Goal 3.8 (achieve UHC).

Challenges

• Manufacturer compliance: Some manufacturers may respond by withdrawing products from the market rather than accepting reduced margins, leading to supply shortages.
• Innovation vs. affordability tension: Stringent price controls can discourage R&D investment in novel cancer therapies.
• Enforcement gaps: Informal retailers may not update MRPs promptly; monitoring capacity of state drug control authorities is uneven.
• Diagnostic bottleneck: Price controls address treatment costs but not the diagnostic access gap — many patients in rural India are still diagnosed at advanced stages when treatment costs are highest.
• Patent barrier: Patented cancer drugs (originator brands) may fall outside DPCO's immediate reach; compulsory licensing under Section 84 of the Patents Act 1970 is an option but rarely used.

Government Initiatives

• Ayushman Bharat – PM Jan Arogya Yojana (AB-PMJAY): World's largest government health assurance scheme; covers secondary and tertiary care hospitalisation up to ₹5 lakh per family per year.
• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP): Over 10,000 Janaushadhi Kendras sell generic medicines at 50–90% lower than branded prices.
• National Cancer Grid (NCG): Network of cancer centres to standardise cancer care.
• National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS): Government programme for early cancer detection and treatment.
• Trade Margin Rationalisation (TMR) — earlier phase: 2019 — 42 anti-cancer drugs had trade margins capped at 30%, significantly reducing MRPs; the 2026 revision expands this to 137 drugs.

Way Forward

• The Parliamentary Standing Committee on Health has recommended expanding the Essential Medicines List to include more cancer drugs under scheduled price control, rather than relying on the Para 19 route.
• India should explore compulsory licensing under Section 84 of the Patents Act 1970 more proactively for high-priced patented cancer therapies, as recommended by the Department-Related Parliamentary Standing Committee on Commerce.
• Strengthening the Pharmacovigilance Programme of India (PvPI) is essential to ensure that quality is not compromised when manufacturers cut margins.
• The National Health Policy 2017's goal of reducing OOP expenditure to 25% of total health expenditure requires comprehensive drug price regulation beyond anti-cancer drugs alone.

Possible Mains Questions

1. Critically examine India's pharmaceutical pricing architecture — how effective is Trade Margin Rationalisation (TMR) as a tool to make essential medicines accessible to the poor? (GS-II, 15 marks)
2. India spends less than 2% of GDP on public health. How does out-of-pocket expenditure on medicines like anti-cancer drugs undermine India's Universal Health Coverage goals? (GS-II, 10 marks)

Possible Prelims MCQs

1. Q. The National Pharmaceutical Pricing Authority (NPPA) is set up under which ministry?
   A. Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals). (NPPA is an executive body, not a statutory body.)
2. Q. Paragraph 19 of the Drug Price Control Order (DPCO) 2013 empowers the government to: (a) fix ceiling prices of scheduled formulations; (b) fix or regulate prices of non-scheduled formulations in public interest; (c) grant compulsory licences for patented drugs; (d) approve new drug formulations for the market.
   A. (b). Para 19 is specifically for public-interest price intervention on non-scheduled drugs.
3. Q. The DPCO 2013 is issued under which parent legislation?
   A. Essential Commodities Act, 1955 (Section 3).
4. Q. Trade Margin Rationalisation (TMR) in pharmaceuticals refers to: (a) setting a maximum manufacturing price; (b) capping the mark-up added by wholesalers and retailers over the manufacturer's price; (c) controlling import tariffs on drug ingredients; (d) fixing the GST rate on medicines.
   A. (b).
5. Q. Which Directive Principle of State Policy (DPSP) provides the constitutional basis for drug price regulation in India?
   A. Article 47 — the State shall regard improvement of public health as a primary duty.

Essay Dimensions

1. Access to medicines as a fundamental right: the case for stronger pharmaceutical price regulation in India.
2. Patent monopoly vs. public health: how can India use compulsory licensing without discouraging innovation?
3. Universal Health Coverage and India's journey: achievements, gaps, and the road to 2030.
4. Out-of-pocket health expenditure: the silent driver of poverty in rural India.
5. Regulating trade margins vs. fixing ceiling prices: which approach is better for drug affordability?

Interview Questions

1. The NPPA is not a statutory body. Does this limit its regulatory authority? What reforms would strengthen it?
2. How does trade margin rationalisation differ from ceiling price fixation under the DPCO 2013? Which is more effective for cancer drugs specifically?
3. India uses compulsory licensing rarely. Given the high price of cancer drugs, is this the right approach?
4. How does Ayushman Bharat interact with NPPA's price control mechanism to improve access to cancer care?
5. What is the role of the Jan Aushadhi scheme in complementing NPPA's price regulation mandate?

FAQ

What is the DPCO 2013 and who issues it?

The Drug Price Control Order (DPCO) 2013 is a subordinate legislation issued by the Central Government under Section 3 of the Essential Commodities Act, 1955. It governs the pricing of pharmaceutical products in India, distinguishing between scheduled formulations (whose ceiling prices are fixed by NPPA) and non-scheduled formulations (market-priced but subject to public-interest intervention under Para 19).

Why are only 'trade margins' being capped rather than the drug's overall price?

These 137 anti-cancer drugs are non-scheduled drugs. Under the DPCO 2013, the government cannot directly fix their ceiling price (as it does for scheduled drugs). Instead, it uses Paragraph 19 to cap the percentage mark-up that distributors and retailers can add to the manufacturer's price, which indirectly reduces the MRP paid by patients.

Will these revised prices apply to hospitals under Ayushman Bharat as well?

Yes. All retailers, hospitals, and distributors — including those empanelled under Ayushman Bharat – PM Jan Arogya Yojana — are required to charge revised prices from 9 November 2026. Hospitals that charge more than the revised MRP will be in violation of the DPCO 2013.

Further Reading

• NPPA official portal: https://www.nppa.gov.in
• Department of Pharmaceuticals, MoC&F: https://pharmaceuticals.gov.in
• DPCO 2013 — India Code: https://www.indiacode.nic.in